Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here at the end of each week.
Clavis' Hellebø takes the helm at Sir Chris Evans-backed ReNeuron
Biotech vet Olav Hellebø has taken the reins at ReNeuron, a regenerative medicines company that is slated to relocate to Wales next year. Hellebø had led Norway's Clavis, which experienced a couple of key setbacks in an attempt to develop new cancer therapies. Sir Chris Evans, the high-flying U.K. biotech entrepreneur, is one of the key players backing ReNeuron. Story
Biotech > Agilis Biotherapeutics appointed Dr. Mark Pykett as president and CEO. Release > Nicole DeBerg joined the J. Craig Venter Institute as the organization's COO. Release > Gregg Stetsko is leaving his post as vice president of research and development at Flamel Technologies ($FLML). Release > Afferent Pharmaceuticals named Kathleen Sereda Glaub CEO. Release > Darrell Lee has retired as vice president of MOCON ($MOCO), and Elissa Lindsoe was named as his successor. Release > pSivida ($PSDV) has elected James Barry to its board of directors. Release > To-BBB brought on Dr. Anders Harfstrand as the company's CEO. Release > Second Genome appointed Karim Dabbagh as its chief scientific officer. Release > Richard Gastineau joined Y-Prime as its chief operating officer. Release > Abcam brought on Alan Hirzel to succeed Jonathan Milner as its CEO. Release > Bruno Lucidi is the new CEO of Karolinska Development companies Aprea and Akinion Pharmaceuticals. Release > Aptose Biosciences appointed Dr. Stephen Howell as its chief medical officer. Release > CollPlant named Nadav Orr its vice president of research and development. Release > RxTrials hired Yvonne McCracken as its vice president of clinical operations and compliance. Release > Ignyta ($RXDX) appointed Robert Wild as its chief scientific officer and senior vice president of research. Release > Batu Biologics named Dr. Hong Ma its chief scientific officer. Release > Pivotal Therapeutics appointed Prakash Gowd as its chief financial officer. Release Pharma > Cyclacel Pharmaceuticals ($CYCC) has appointed Samuel Barker to its board of directors. Release > Acucela appointed pharma exec Brian O'Callaghan as its new president and chief operating officer. He will also serve as interim CFO. Release Biotech IT > Jim Corrigan will assume the role of president and CEO at ERT. Corrigan has served as executive vice president and chief operating officer since August 2013. Release Pharma Marketing > Scott Peoples signed on as the vice president of marketing at Marrone Bio Innovations. Release |
||||
